Clarivate sees obesity drug market rising to $56.8 billion by 2033, flags next-generation therapy innovators

PUBT · 2d ago
Clarivate sees obesity drug market rising to $56.8 billion by 2033, flags next-generation therapy innovators
  • Clarivate published a Companies to Watch report on next-generation obesity therapies beyond first-generation GLP-1 drugs.
  • Forecast obesity-drug sales across major markets rising to $56.8 billion by 2033 from $5.5 billion in 2023.
  • Report flagged seven emerging developers, highlighting oral treatments, ultra-long-acting options, muscle-preserving approaches, non-incretin mechanisms.
  • Deal activity in the sector nearly doubled between 2023 and 2024, reflecting intensifying investment in differentiated obesity technologies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.